CLINICAL_TRIALS ClinicalTrials.gov record update

A MASTER PHASE 1/2/3 PROTOCOL TO INVESTIGATE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF VARIANT-ADAPTED BNT162b2 RNA-BASED VACCINE CANDIDATE(S) IN HEALTHY CHILDREN

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT05543616
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-08-07T00:07:35.972201+00:00
Published At: 2026-08-06T00:00:00+00:00
Record Updated At: 2026-08-06
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["SARS-CoV-2 Virus", "Severe Acute Respiratory Syndrome Coronavirus 2", "COVID-19"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2026-08-06"
protocolSection.identificationModule.nctId: "NCT05543616"
protocolSection.identificationModule.officialTitle: "A MASTER PHASE 1/2/3 PROTOCOL TO INVESTIGATE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF VARIANT-ADAPTED BNT162b2 RNA-BASED VACCINE CANDIDATE(S) IN HEALTHY CHILDREN"
protocolSection.statusModule.overallStatus: "COMPLETED"
protocolSection.designModule.phases: ["PHASE3"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: ""

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.